← Leaderboards
Lazar Vujanovic
University Of Pittsburgh At Pittsburgh
$956,572
Attributed
$2,869,715
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $762.4K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,869,715 · 1
By mechanism
R01$2,869,715 · 1
Top collaborators
- Robert L Ferris4 shared
- Jing Hong Wang4 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Surinder Kumar Batra$34,830,369
- John Munn Kirkwood$15,450,309
- Randall Brand$11,652,606
- Jeremy N Rich$24,023,429
- Hassane M Zarour$16,372,397
Others in their field
Other Rising Stars on “Future”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Mari Ostendorf · University Of Washington$51,931,230
- Jeffrey Leintz · National Opinion Research Center$40,628,545
- Eric M Benway · Woods Hole Oceanographic Institution$32,293,242
- Walt Lee$25,884,232
- Cyrus Wadia · Activate Global, Inc.$24,000,000
Research focus
FutureHuman PapillomavirusCombination ImmunotherapyCoupledAntibodiesHead And Neck Squamous Cell CarcinomaAnti-Pd-L1Anti-Ctla4AftercareBloodCancer ImmunotherapyCancer PatientCancer PrognosisCancer TypeCarcinogensCd8b1 GeneCd8-Positive T-LymphocytesAnti-Pd-L1 TherapyCellsCellular Indexing Of Transcriptomes And Epitopes By SequencingCheckpoint TherapyClinical TrialsClonal ExpansionImmune Checkpoint Inhibitor
Grant awards (4)
Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs$762,411
R01 · FY2025 · DE
Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs$747,163
R01 · FY2024 · DE
Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs$681,410
R01 · FY2023 · DE
Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs$678,731
R01 · FY2022 · DE